Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Henriksen, Kim ; Byrjalsen, Inger ; Qvist, Per ; Beck-Nielsen, Henning ; Hansen, Gitte ; Riis, Bente J ; Perrild, Hans ; Svendsen, Ole Lander ; Gram, Jeppe ; Karsdal, Morten A ; Christiansen, Claus ; BALLET Trial Investigators. / Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo : a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy. In: Diabetes - Metabolism: Research and Reviews (Print Edition). 2011 ; Vol. 27, No. 4. pp. 392-401.

Bibtex

@article{7a2782b1da9c47c68866ad17dc7736f5,
title = "Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy",
abstract = "Treatment of patients with perioxisome proliferator-activated receptor-γ full agonists are associated with weight gain, heart failure, peripheral oedema, and bone loss. However, the safety of partial perioxisome proliferator-activated receptor-γ agonists has not been established in a clinical trial. The BALaglitazone glucose Lowering Efficacy Trial aimed to establish the glucose-lowering effects and safety parameters of the perioxisome proliferator-activated receptor-γ partial agonist balaglitazone in diabetic patients on stable insulin therapy.",
keywords = "Aged, Blood Glucose, Body Composition, Bone Density, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Female, Hemoglobin A, Glycosylated, Humans, Hypoglycemic Agents, Insulin, Male, Middle Aged, PPAR gamma, Quinazolines, Thiazolidinediones, Water-Electrolyte Balance, Weight Gain",
author = "Kim Henriksen and Inger Byrjalsen and Per Qvist and Henning Beck-Nielsen and Gitte Hansen and Riis, {Bente J} and Hans Perrild and Svendsen, {Ole Lander} and Jeppe Gram and Karsdal, {Morten A} and Claus Christiansen and {BALLET Trial Investigators}",
note = "Copyright {\textcopyright} 2011 John Wiley & Sons, Ltd.",
year = "2011",
doi = "10.1002/dmrr.1187",
language = "English",
volume = "27",
pages = "392--401",
journal = "Diabetes - Metabolism: Research and Reviews",
issn = "1520-7552",
publisher = "John/Wiley & Sons Ltd",
number = "4",

}

RIS

TY - JOUR

T1 - Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo

T2 - a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy

AU - Henriksen, Kim

AU - Byrjalsen, Inger

AU - Qvist, Per

AU - Beck-Nielsen, Henning

AU - Hansen, Gitte

AU - Riis, Bente J

AU - Perrild, Hans

AU - Svendsen, Ole Lander

AU - Gram, Jeppe

AU - Karsdal, Morten A

AU - Christiansen, Claus

AU - BALLET Trial Investigators

N1 - Copyright © 2011 John Wiley & Sons, Ltd.

PY - 2011

Y1 - 2011

N2 - Treatment of patients with perioxisome proliferator-activated receptor-γ full agonists are associated with weight gain, heart failure, peripheral oedema, and bone loss. However, the safety of partial perioxisome proliferator-activated receptor-γ agonists has not been established in a clinical trial. The BALaglitazone glucose Lowering Efficacy Trial aimed to establish the glucose-lowering effects and safety parameters of the perioxisome proliferator-activated receptor-γ partial agonist balaglitazone in diabetic patients on stable insulin therapy.

AB - Treatment of patients with perioxisome proliferator-activated receptor-γ full agonists are associated with weight gain, heart failure, peripheral oedema, and bone loss. However, the safety of partial perioxisome proliferator-activated receptor-γ agonists has not been established in a clinical trial. The BALaglitazone glucose Lowering Efficacy Trial aimed to establish the glucose-lowering effects and safety parameters of the perioxisome proliferator-activated receptor-γ partial agonist balaglitazone in diabetic patients on stable insulin therapy.

KW - Aged

KW - Blood Glucose

KW - Body Composition

KW - Bone Density

KW - Diabetes Mellitus, Type 2

KW - Dose-Response Relationship, Drug

KW - Double-Blind Method

KW - Drug Therapy, Combination

KW - Female

KW - Hemoglobin A, Glycosylated

KW - Humans

KW - Hypoglycemic Agents

KW - Insulin

KW - Male

KW - Middle Aged

KW - PPAR gamma

KW - Quinazolines

KW - Thiazolidinediones

KW - Water-Electrolyte Balance

KW - Weight Gain

U2 - 10.1002/dmrr.1187

DO - 10.1002/dmrr.1187

M3 - Journal article

C2 - 21328517

VL - 27

SP - 392

EP - 401

JO - Diabetes - Metabolism: Research and Reviews

JF - Diabetes - Metabolism: Research and Reviews

SN - 1520-7552

IS - 4

ER -

ID: 34796416